

**THE ISRAEL BALLET**  
 Takoma Park/Silver Spring Performing Arts Center  
 Montgomery College • www.montgomerycollege.edu/PAC  
 7985 Georgia Avenue • Silver Spring, MD 20910

**DON QUIXOTE: Fri., February 26, 2010 at 8pm**  
**TRIPLE BILL: A COMPILATION OF CLASSICAL WORKS**  
**Sat., February 27, 2010 at 8pm**

**Medifast**  
**HEALTHY CHALLENGE**  
 The Gazette's Weight Loss Competition  
[click here to register for the 2010 Healthy Challenge](#)

# Gazette.Net

Maryland Community Newspapers Online

Now 41° Tue 50°/34° Wed 45°/31° 5-day forecast Traffic

Search    
 Advanced Search

Montgomery | Prince George's | Frederick | Sports | Business | Politics | Entertainment | Opinion | Calendar | Autos | Homes | GazetteBuyandSell.com | Classifieds **JOBS** | Help

News by Community | Sports by Community

Friday, Feb. 19, 2010

## BioWatch: Germantown's Psyadon tackles a 'terribly disfiguring' disease

Pharmaceutical company to launch study of compound for rare genetic disorder

by Robert Rand | Staff Writer



**More News**

- Food bank prepares pantry for 'extremely heavy' demands
- Book details history of Petersville, Brunswick black churches
- Senior winter Olympic games include ice hockey, curling events
- Cheverly native balances politics and artistry
- Residents remember 'Silent Spring'

Almost a year and a half ago, Richard E. Chipkin landed an \$8 million investment in his tiny bioscience company, changed its name and research focus, and licensed a compound that shows promise as a treatment for a debilitating genetic condition that afflicts a relative handful of people.

Chipkin, who holds a doctorate in pharmacology, is president and CEO of Psyadon Pharmaceuticals of Germantown, which was founded in 2004 as Ruxton Pharmaceuticals. The company recently announced that the U.S. Food and Drug Administration had accepted its investigational new drug application to study ecopipam in patients with Lesch-Nyhan disease, a genetic disorder that affects from 500 to 1,000 Americans.

The initial study, to evaluate the safety and tolerability of ecopipam in adults, adolescents and children with Lesch-Nyhan, will be conducted at Emory University in Atlanta. Ecopipam is a selective dopamine D1 receptor antagonist.

Why target Lesch-Nyhan, a disease that is passed from mothers to sons and is characterized by a buildup of uric acid in the body, an inability to walk because of joint problems and, perhaps most disturbing, self-mutilation?

Most importantly for humanitarian reasons, Chipkin said.

"It's a terribly disfiguring problem," he said. Patients, many of whom are institutionalized because they need round-the-clock care and restraints, have their teeth removed to prevent them from biting off their fingers.

An effective treatment "is desperately needed," Chipkin said. "If we can, we should bring it to market."

Some of the other symptoms of Lesch-Nyhan have been brought under control through medication, he said, keeping patients alive past childhood into their 30s.

Ecopipam — which Psyadon licensed from Schering, where Chipkin once worked — acts on the central nervous system and might help Lesch-Nyhan patients control their self-injurious behavior and other motor symptoms, too, he said.

Just because a disease affects relatively few people doesn't mean an effective treatment can't be profitable, Chipkin said, pointing to biotech giant Genzyme, which "makes a living from orphan disease drugs."

Ecopipam has received such orphan drug designation from the FDA, putting the product on a regulatory fast track, letting Psyadon avoid certain fees and giving the company market exclusivity for seven years in the U.S. and 10 years in Europe, he said.

The compound could be effective in treating other disorders involving the central nervous system; Chipkin said he taps consultants for advice on other possible uses.

Psyadon itself is "run as a virtual company," he said, with only one full-time employee — himself. He also constitutes half of the company's board. Its other member is James Barrett, general partner at New Enterprise Associates of Chevy Chase, which made the \$8 million investment in Psyadon in October 2008.

**Know Your Neighborhoods**

Before you buy a home, learn all about the neighborhood, exclusively on Gazette.Net HOMES >>

**Gazette.Net Homes**

**FEATURED JOBS**

- DENTAL ASSISTANT Group Practice Seeks Experienced.
- FITZGERALD AUTO MALL A Recession Proof Business...
- RECEPTIONIST Pediatric Dental office seeking a fr.
- Medical Records Coordinator (FT 40hrs/wk) Coordin.

[See all jobs](#)

**Montgomery College**  
 Workforce Development & Continuing Education

**REGISTER FOR SPRING CLASSES**

[Click Here](#)

**ASBURY**  
 METHODIST VILLAGE

The areas most well-known best kept secret in retirement living

**NEIGHBORHOOD LIVING**

**WHAT'S NEW**

**TOP JOBS**

- Production Coordinator The Gazette a Post Newsweek
- Executive Assistant Gaithersburg non-profit. Cand.
- Advertising Sales Consultant Do you like freedom .
- HOLIDAY INN GAITHERSBURG Is currently hiring for .

[See all jobs](#)

**SEARCH DIRECTORIES**

Search all directories

[Place a classifieds ad now](#)

**Hire Locally**

from ONLY \$99

**The Gazette**

Find highly qualified, very local candidates at one of the lowest prices anywhere!